HRP960307A2 - Novel peptides derived from human heat shock protein 60 for treatment of diabetes - preparations, methods and kits - Google Patents

Novel peptides derived from human heat shock protein 60 for treatment of diabetes - preparations, methods and kits Download PDF

Info

Publication number: HRP960307A2
Authority: HR; Croatia
Prior art keywords: peptide; cells; hsp60; iddm; antigen
Prior art date: 1995-06-30

Application number

HR114407A

Other languages

English (en)

Croatian (hr)

Inventor

Irun R Cohen

Dana Elias

Rivka Abulafia

Jana Bockova

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-30

Filing date

1996-07-01

Publication date

1998-04-30

1996-07-01 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1998-04-30 Publication of HRP960307A2 publication Critical patent/HRP960307A2/hr

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 154
102000004196 processed proteins & peptides Human genes 0.000 title claims description 63
238000000034 method Methods 0.000 title claims description 31
238000011282 treatment Methods 0.000 title claims description 30
238000002360 preparation method Methods 0.000 title claims description 12
206010012601 diabetes mellitus Diseases 0.000 title description 34
101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 title description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 70
102000006303 Chaperonin 60 Human genes 0.000 claims description 69
108010058432 Chaperonin 60 Proteins 0.000 claims description 69
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 63
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 59
239000000427 antigen Substances 0.000 claims description 48
102000036639 antigens Human genes 0.000 claims description 47
108091007433 antigens Proteins 0.000 claims description 47
238000012360 testing method Methods 0.000 claims description 36
210000004369 blood Anatomy 0.000 claims description 23
239000008280 blood Substances 0.000 claims description 23
210000004027 cell Anatomy 0.000 claims description 17
230000004044 response Effects 0.000 claims description 15
230000006052 T cell proliferation Effects 0.000 claims description 9
239000002773 nucleotide Substances 0.000 claims description 9
125000003729 nucleotide group Chemical group 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
102000004127 Cytokines Human genes 0.000 claims description 8
108090000695 Cytokines Proteins 0.000 claims description 8
210000004698 lymphocyte Anatomy 0.000 claims description 7
210000005087 mononuclear cell Anatomy 0.000 claims description 7
238000003745 diagnosis Methods 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 claims description 6
239000012634 fragment Substances 0.000 claims description 5
238000011534 incubation Methods 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 5
102000004169 proteins and genes Human genes 0.000 claims description 5
238000002965 ELISA Methods 0.000 claims description 4
238000010348 incorporation Methods 0.000 claims description 4
210000002700 urine Anatomy 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
108010074328 Interferon-gamma Proteins 0.000 claims description 3
102000003814 Interleukin-10 Human genes 0.000 claims description 3
108090000174 Interleukin-10 Proteins 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
102100037850 Interferon gamma Human genes 0.000 claims description 2
108010002350 Interleukin-2 Proteins 0.000 claims description 2
102000000588 Interleukin-2 Human genes 0.000 claims description 2
102000004889 Interleukin-6 Human genes 0.000 claims description 2
108090001005 Interleukin-6 Proteins 0.000 claims description 2
102000018697 Membrane Proteins Human genes 0.000 claims description 2
108010052285 Membrane Proteins Proteins 0.000 claims description 2
206010040914 Skin reaction Diseases 0.000 claims description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims description 2
230000003436 cytoskeletal effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000002706 hydrostatic effect Effects 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims description 2
239000002243 precursor Substances 0.000 claims description 2
238000003127 radioimmunoassay Methods 0.000 claims description 2
230000035483 skin reaction Effects 0.000 claims description 2
231100000430 skin reaction Toxicity 0.000 claims description 2
239000007790 solid phase Substances 0.000 claims description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
239000003431 cross linking reagent Substances 0.000 claims 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
238000010382 chemical cross-linking Methods 0.000 claims 1
239000003550 marker Substances 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 68
102100036948 DNA polymerase epsilon subunit 4 Human genes 0.000 description 29
241000699666 Mus <mouse, genus> Species 0.000 description 23
230000009696 proliferative response Effects 0.000 description 15
102100024067 Inhibitor of growth protein 2 Human genes 0.000 description 13
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
230000001363 autoimmune Effects 0.000 description 12
239000008103 glucose Substances 0.000 description 12
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 11
230000008569 process Effects 0.000 description 11
241001529936 Murinae Species 0.000 description 10
230000002269 spontaneous effect Effects 0.000 description 10
241000611421 Elia Species 0.000 description 9
230000002163 immunogen Effects 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
230000005867 T cell response Effects 0.000 description 7
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
238000011161 development Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
206010018429 Glucose tolerance impaired Diseases 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
230000002788 anti-peptide Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
102000046432 human HSPD1 Human genes 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 2
102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical group CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
102000008214 Glutamate decarboxylase Human genes 0.000 description 1
108091022930 Glutamate decarboxylase Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101150023414 HSP60 gene Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001904 diabetogenic effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000017307 interleukin-4 production Effects 0.000 description 1
ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical group [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

HR114407A 1995-06-30 1996-07-01 Novel peptides derived from human heat shock protein 60 for treatment of diabetes - preparations, methods and kits HRP960307A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL11440795A IL114407A0 (en)	1995-06-30	1995-06-30	Novel peptides and pharmaceutical compositions comprising them

Publications (1)

Publication Number	Publication Date
HRP960307A2 true HRP960307A2 (en)	1998-04-30

Family

ID=11067704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR114407A HRP960307A2 (en)	1995-06-30	1996-07-01	Novel peptides derived from human heat shock protein 60 for treatment of diabetes - preparations, methods and kits

Country Status (19)

Country	Link
US (1)	US6682897B1 (de)
EP (1)	EP0845943B1 (de)
KR (1)	KR100454554B1 (de)
CN (1)	CN1102598C (de)
AR (1)	AR003446A1 (de)
AT (1)	ATE290315T1 (de)
AU (1)	AU710882B2 (de)
CA (1)	CA2225675C (de)
CZ (1)	CZ295110B6 (de)
DE (1)	DE69634438T2 (de)
DK (1)	DK0845943T3 (de)
ES (1)	ES2239770T3 (de)
HR (1)	HRP960307A2 (de)
HU (1)	HUP9901688A3 (de)
IL (2)	IL114407A0 (de)
NO (1)	NO320715B1 (de)
UY (1)	UY24270A1 (de)
WO (1)	WO1997001959A1 (de)
ZA (1)	ZA965565B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
ATE249046T1 (de) *	1996-05-14	2003-09-15	Winnacker Ernst Ludwig Prof	Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
AU784623B2 (en) *	1999-12-15	2006-05-18	Develogen Israel Ltd.	Fragments and antagonists of heat shock protein 60
WO2002016549A2 (en) *	2000-08-25	2002-02-28	Yeda Research And Development Co. Ltd.	METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
EP2157101B1 (de)	2002-01-31	2014-09-24	Andromeda Bio Tech Ltd.	HSP-Peptide und Analoga zur Modulation von Immunantworten mittels antigenpräsentierenden Zellen
AU2003209623A1 (en) *	2002-02-19	2003-09-09	Yeda Research And Development Co. Ltd.	Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
AU2003230181A1 (en)	2002-05-21	2003-12-02	Yeda Research And Development Co. Ltd.	Dna vaccines encoding heat shock proteins
WO2004098489A2 (en) *	2003-05-12	2004-11-18	Peptor Ltd.	Compositions and methods for modulation of specific epitopes of hsp60
EP1687423A4 (de) *	2003-11-24	2007-04-18	Yeda Res & Dev	Für hsp60-peptidfragmente codierende dna-impfstoffe zur behandlung von autoimmunkrankheiten
CA2595520A1 (en)	2004-01-28	2005-08-11	Develogen Israel Ltd.	Hsp therapy in conjunction with a low antigenicity diet
WO2006072946A2 (en) *	2005-01-04	2006-07-13	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
CU23701A1 (es)	2008-12-29	2011-09-21	Ct Ingenieria Genetica Biotech	Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
KR101307132B1 (ko) *	2010-02-04	2013-09-10	이화여자대학교 산학협력단	비정상적 세포 증식 억제용 약제학적 조성물
ITCO20120007A1 (it)	2012-02-21	2013-08-22	Nuovo Pignone Srl	Dispositivo di filtraggio dell'aria in ingresso per un impianto
CN104203263A (zh)	2012-03-01	2014-12-10	耶达研究与发展有限公司	利用HSP60衍生肽再生胰岛β细胞
WO2013128450A1 (en)	2012-03-01	2013-09-06	Yeda Research And Development Co. Ltd.	Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
JP2019523633A (ja) *	2016-04-29	2019-08-29	アライムファーマシューティカルズ，インコーポレーテッド	組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
CN111035755B (zh) *	2020-01-08	2023-04-14	中国医学科学院医学生物学研究所	一种1型糖尿病疫苗及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5242823A (en) *	1986-03-07	1993-09-07	International Genetic Engineering, Inc.	Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen
US4976958A (en) *	1987-02-26	1990-12-11	Scripps Clinic And Research Foundation	Mycobacterial recombinants and peptides
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus

1995
- 1995-06-30 IL IL11440795A patent/IL114407A0/xx unknown
1996
- 1996-06-28 UY UY24270A patent/UY24270A1/es unknown
- 1996-07-01 CA CA2225675A patent/CA2225675C/en not_active Expired - Lifetime
- 1996-07-01 CZ CZ19974117A patent/CZ295110B6/cs not_active IP Right Cessation
- 1996-07-01 HR HR114407A patent/HRP960307A2/hr not_active Application Discontinuation
- 1996-07-01 AR ARP960103410A patent/AR003446A1/es not_active Application Discontinuation
- 1996-07-01 DE DE69634438T patent/DE69634438T2/de not_active Expired - Lifetime
- 1996-07-01 AU AU64845/96A patent/AU710882B2/en not_active Expired
- 1996-07-01 ZA ZA9605565A patent/ZA965565B/xx unknown
- 1996-07-01 DK DK96924372T patent/DK0845943T3/da active
- 1996-07-01 CN CN96196403A patent/CN1102598C/zh not_active Expired - Lifetime
- 1996-07-01 WO PCT/US1996/011375 patent/WO1997001959A1/en not_active Ceased
- 1996-07-01 ES ES96924372T patent/ES2239770T3/es not_active Expired - Lifetime
- 1996-07-01 KR KR1019970709962A patent/KR100454554B1/ko not_active Expired - Fee Related
- 1996-07-01 AT AT96924372T patent/ATE290315T1/de active
- 1996-07-01 HU HU9901688A patent/HUP9901688A3/hu not_active Application Discontinuation
- 1996-07-01 EP EP96924372A patent/EP0845943B1/de not_active Expired - Lifetime
- 1996-07-01 IL IL12275796A patent/IL122757A/en not_active IP Right Cessation
1997
- 1997-12-29 NO NO19976094A patent/NO320715B1/no not_active IP Right Cessation
2000
- 2000-07-11 US US09/613,743 patent/US6682897B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK0845943T3 (da)	2005-07-11
HUP9901688A2 (hu)	1999-09-28
DE69634438T2 (de)	2006-02-09
IL122757A (en)	2001-07-24
CA2225675C (en)	2010-09-21
KR100454554B1 (ko)	2005-04-06
CN1102598C (zh)	2003-03-05
AR003446A1 (es)	1998-08-05
AU6484596A (en)	1997-02-05
JP3955627B2 (ja)	2007-08-08
EP0845943A1 (de)	1998-06-10
NO976094D0 (no)	1997-12-29
ES2239770T3 (es)	2005-10-01
MX9800191A (es)	1998-05-31
DE69634438D1 (de)	2005-04-14
IL122757A0 (en)	1998-08-16
NO320715B1 (no)	2006-01-23
NO976094L (no)	1998-02-02
AU710882B2 (en)	1999-09-30
CA2225675A1 (en)	1997-01-23
KR19990028640A (ko)	1999-04-15
WO1997001959A1 (en)	1997-01-23
CZ295110B6 (cs)	2005-05-18
JPH11509196A (ja)	1999-08-17
CN1193889A (zh)	1998-09-23
HUP9901688A3 (en)	1999-12-28
US6682897B1 (en)	2004-01-27
ZA965565B (en)	1997-02-26
IL114407A0 (en)	1995-10-31
EP0845943A4 (de)	2002-04-10
UY24270A1 (es)	2000-12-29
EP0845943B1 (de)	2005-03-09
CZ411797A3 (cs)	1998-06-17
ATE290315T1 (de)	2005-03-15

Legal Events

Date	Code	Title	Description
1998-04-30	A1OB	Publication of a patent application
1999-06-14	ODBC	Application rejected

Publication	Publication Date	Title
JP3165148B2 (ja)	2001-05-14	インスリン依存性糖尿病の診断と治療
AU710882B2 (en)	1999-09-30	Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
CA2208274C (en)	2005-12-06	Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
US6110746A (en)	2000-08-29	Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US5780034A (en)	1998-07-14	Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents
US5578303A (en)	1996-11-26	Diagnosis and treatment of insulin dependent diabetes mellitus
US6180103B1 (en)	2001-01-30	Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
JP3955627B6 (ja)	2007-12-26	糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット
JP2007119482A (ja)	2007-05-17	糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット
MXPA98000191A (en)	1998-10-23	Novedous peptides derived from human protein 60 produced by thermal shock, for the treatment of diabetes, compositions, methods and equi
IL111361A (en)	1998-12-06	Polypeptides derived from hHSP65 and pharmaceutical compositions comprising them for prevention or treatment of insulin dependent diabetes mellitus (IDDM)